NCT07131475View on ClinicalTrials.gov

Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

August 31, 2029

Conditions
Blast Injury
Interventions
DRUG

PBR28 TSPO PET

Each SEAL participant will undergo brain imaging with PBR28 translocator protein (TSPO) positron emission tomography (PET) at study enrollment and at 1-year follow up.

All Listed Sponsors
collaborator

University of South Florida

OTHER

collaborator

Navy SEAL Foundation

UNKNOWN

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Uniformed Services University of the Health Sciences

FED

lead

Massachusetts General Hospital

OTHER